Literature DB >> 10480579

Environmental exposure unit: a system to test anti-allergic treatment.

J H Day1, M P Briscoe.   

Abstract

LEARNING
OBJECTIVES: Reading this article will enable readers to recognize the Environmental Exposure Unit (EEU), its historic development and its current role as a system to test anti-allergic treatment; to recognize clinical relevance of this test system and its relationship with other pollen challenge methods of evaluation of anti-allergic medication; and, to recognize variables associated with standard clinical studies of anti-allergic medication. Readers will review four studies of antihistamines tested in the Environmental Exposure Unit, three studies on nasal corticosteroids, one on topical eye drops and one on immunotherapy conducted in the EEU. DATA SOURCES: The EEU has been in operation since 1985 preceded by a prototype challenge system to assess respiratory effects of urea formaldehyde foam insulation. A number of studies on the onset of action and efficacy of different antihistamines and nasal corticosteroids as well as other treatments have been completed producing accurate and consistent results influenced to some extent by study designs. STUDY SELECTION: Studies of commonly used antihistamines and nasal corticosteroids are discussed in detail and represent several of the studies undertaken to date in the EEU.
RESULTS: Controlled ragweed pollen exposure using the EEU has shown that some antihistamines demonstrate an onset of action within 30 minutes while others have taken up to 3 hours to produce significant effect. Nasal corticosteroids evidenced the onset of clinical improvement at 5 to 6 hours with significance over placebo between 6 and 12 hours depending on dose.
CONCLUSION: The EEU is an effective pollen delivery system that accurately and consistently determines the onset of action and efficacy of anti-allergic treatment in large groups of subjects. It eliminates variables associated with various other methods of evaluation of these medications but does not supplant the need for such evaluations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480579     DOI: 10.1016/S1081-1206(10)62616-6

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  9 in total

1.  The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies.

Authors:  Anne K Ellis; Mena Soliman; Lisa Steacy; Marie-Ève Boulay; Louis-Philippe Boulet; Paul K Keith; Harissios Vliagoftis; Susan Waserman; Helen Neighbour
Journal:  Allergy Asthma Clin Immunol       Date:  2015-04-24       Impact factor: 3.406

2.  Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit.

Authors:  Michelle L North; Terry J Walker; Lisa M Steacy; Barnaby G Hobsbawn; Richard J Allan; Frances Hackman; Xiaoqun Sun; Andrew G Day; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2014-07-03       Impact factor: 3.406

3.  Clinical validation of controlled grass pollen challenge in the Environmental Exposure Unit (EEU).

Authors:  Anne K Ellis; Lisa M Steacy; Barnaby Hobsbawn; Caroline E Conway; Terry Jb Walker
Journal:  Allergy Asthma Clin Immunol       Date:  2015-01-27       Impact factor: 3.406

4.  Technical and clinical validation of an environmental exposure unit for ragweed.

Authors:  Paul J Gomes; Keith J Lane; Endri Angjeli; Linda Stein; Mark B Abelson
Journal:  J Asthma Allergy       Date:  2016-12-14

5.  Clinical validation of controlled exposure to birch pollen in the Environmental Exposure Unit (EEU).

Authors:  Anne K Ellis; Mena Soliman; Lisa M Steacy; Daniel E Adams; Barnaby Hobsbawn; Terry J B Walker
Journal:  Allergy Asthma Clin Immunol       Date:  2016-10-19       Impact factor: 3.406

6.  Technical and clinical validation of the Allergen BioCube® for timothy grass.

Authors:  Endri Angjeli; Paul Gomes; Keith J Lane; Linda Stein; Mark B Abelson
Journal:  Immun Inflamm Dis       Date:  2017-02-02

7.  Birch allergen challenges in allergic conjunctivitis using standard conjunctival allergen challenge and environmental exposure chamber.

Authors:  Alina Gherasim; Jean-Luc Fauquert; Nathalie Domis; Xavier Siomboing; Frederic de Blay
Journal:  Clin Transl Allergy       Date:  2021-08-17       Impact factor: 5.871

8.  Cat allergen exposure in a naturalistic exposure chamber: A prospective observational study in cat-allergic subjects.

Authors:  William H Yang; Suzanne Kelly; Laura Haya; Rym Mehri; Divya Ramesh; Michelle DeVeaux; Claire Q Wang; Pretty Meier; Sumit Narula; Furat Shawki; Ryan Pennington; Lorah Perlee; Meagan P O'Brien
Journal:  Clin Exp Allergy       Date:  2022-01-14       Impact factor: 5.401

9.  A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis.

Authors:  Anne K Ellis; Yifei Zhu; Lisa M Steacy; Terry Walker; James H Day
Journal:  Allergy Asthma Clin Immunol       Date:  2013-05-01       Impact factor: 3.406

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.